stars 1 stars 2 stars 3

At Cellectricon, we create new avenues for neuroscience drug discovery. Our mission is to create outstanding value for our Clients through highly customized in vitro neurobiology services delivering scientific excellence, innovation, and quality of the highest of standards. With a broad platform for in vitro neurobiology research, we help you to: • Accelerate your early R&D process and reduce your time-to-decision making • Obtain novel insights into disease biology and identify targets and lead compounds with potential to produce first-in-class medicines • Benefit from truly collaborative services where scientific exchange and open communication are prioritized to ensure project success Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. With the platform, we create complex disease models and assays for functional and morphological screening. We have established service modules in the areas of Neuroinflammation, Peripheral Neuropathies, Neurodegeneration and Neuroplasticity. Through our services, we can accelerate your target and lead discovery programs.

Cellectricon Questions

The Cellectricon annual revenue was $34 million in 2026.

Mattias Karlsson is the CEO of Cellectricon.

17 people are employed at Cellectricon.

The NAICS codes for Cellectricon are [5417, 541, 54171, 541714, 54].

The SIC codes for Cellectricon are [87, 873].

Top Cellectricon Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users